Positive Quality Intervention: Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy

Description of PQI: The purpose of this PQI is to identify patients initiating everolimus therapy and could benefit from prophylaxis with a steroid mouthwash.

Background: Stomatitis is a significant complication associated with mTOR inhibition. In BOLERO-2¹ patients receiving everolimus/exemestane (EVE/EXE), all grade stomatitis was 67%; 25% Grade 2 and 8% Grade 3. The median time to Grade 2 or worse onset was 15.5 days. The incidence of new stomatitis (Grade ≥ 2) plateaued at 6 weeks. In a meta-analysis, 89% of first stomatitis events occurred within 8 weeks. Topical steroids are used to treat aphthous ulcers; anecdotal use of topical steroid prophylaxis has been reported. A trial entitled SWISH² revealed prophylactic use of 0.5 mg/5 mL dexamethasone oral solution markedly decreased the incidence and severity of stomatitis in patients receiving EVE/EXE for metastatic breast cancer. A follow-up study, Alliance MIST Trial, found that the prophylactic use of dexamethasone mouthwash before initiation of everolimus is not superior to reactive use of dexamethasone mouthwash if mouth pain develops. But does continue the support use in reactive use.³

PQI Process: Upon receipt of a new prescription for everolimus⁴
- Identify patients on everolimus or exemestane as they may be a candidate for steroid rinse
- Contact the oncologist to obtain a prescription for mouthwash:
  - Dexamethasone 0.5 mg/5 mL solution - swish 10 mL for 2 minutes and spit out QID for initial 8 weeks *Do not eat or drink for 1 hour post mouth rinse*
- Follow up within 7 days of starting everolimus/steroid mouth rinse

Patient-Centered Activities:
- Provide Oral Chemotherapy Education (OCE) sheet for everolimus
- Encourage patients to use rinse on a scheduled regimen, four times per day
- Brush teeth with soft or extra soft tooth brush
- Advise patients to immediately report any signs or symptoms of mouth sore
- Patient Assistance: NCODA Financial Assistance Tool

References:
4. Afinitor® (everolimus) [package insert].

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 9.11.23